Abstract: Objective: To evaluate the cardiotoxicity of recombinant human endostatin combined with chemotherapy. Methods: A total of 12 patients with cancer who had been treated with recombinant human endostatin combined with chemotherapy were selected and their clinical data were collected. During the treatment, the changes in electrocardiogram (ECG), myocardium enzymogram and left ventricular ejection fraction(LVEF) were monitored. Results: After therapy, CKMB was higher in the middle period to the end of treatment, with a significant difference (P<0.05). ECG changed significantly at the end of treatment compared with its appearance before therapy (P<0.05), while LVEF had no significant changes (P>0.05). Conclusion: Recombinant human endostatin combined with chemotherapy has mild adverse cardiac effects and causes negligible myocardial injury, but it rarely changes cardiac function. CK-MB and ECG can be used as indices for early detection of endostatin-induced cardiotoxicity and should be given more attention during treatment with recombinant human endostatin combined with chemotherapy.